Background
==========

Toxoplasmosis is a disease caused by *Toxoplasma gondii (T. gondii)*. It was described in a North African rodent (*Ctenodactylus gondii*) by Nicolle and Manceaux in 1908 \[[@B1]\]. The *T. gondii* is an obligate intracellular parasite with a complex life cycle, in which homeothermic animals, including humans are capable of acting as intermediate hosts. Humans acquire the parasite by the oral route through the consumption of undercooked meat contaminated with cysts, food products (vegetables and fruits) or water contaminated with oocysts \[[@B1],[@B2]\]. Other routes of transmission are organ transplantation \[[@B3],[@B4]\], blood transfusion \[[@B5]\] and congenital transmission. Butchers, slaughterhouse workers and laboratory personnel that handle cultures and animal models with this parasite are also at risk. However, for the majority of the human population, transmission generally occurs by any of the routes aforementioned \[[@B6]\].

*T. gondii* is found worldwide because a large variety of animals may harbor the parasite and maintain its dissemination. Its broad geographic location is related to several factors, such as contact with infected cat feces and ingestion of mature oocysts \[[@B7]\], food habits and variations in climate. The later has a significant influence on the habitat of *T. gondii;* for instance, an increase in ambient temperature and precipitation can change the humidity of the soil, so that the sporulated oocysts remain viable in the moist environment for a longer period \[[@B8],[@B9]\].

*T. gondii* is considered as the most prevalent parasitic zoonotic disease worldwide \[[@B10]\], since at least one-third of the world's population is infected \[[@B11]\]. Infections caused by *T. gondii* are more frequent in temperate zones than in cold ones; thus, France has the highest prevalence of 90%, whereas the lowest prevalence is found in Alaska with only 1%. However, global warming has caused an increase of *T. gondii* infections in different regions of the world as a result of changing environmental conditions \[[@B8]\].

The mean prevalence of *T. gondii* infection among the Mexican general population is 50%; however, there are variations that depend on climate and humidity. Several risk groups have been identified with high prevalence of infection such as cat owners, people who consume raw or undercooked meat, immunocompromised patients and those that undergo organ transplantation \[[@B3],[@B4]\]. Furthermore, we recently carried out a meta-analysis on reports of toxoplasmosis among Mexican newborns. The weighted prevalence in 4833 asymptomatic newborns was 0.616%, whereas, among 895 symptomatic newborns, the weighed prevalence was 3.02% \[[@B12]\].

Diagnostic testing for toxoplasmosis can be done by staining body fluids or mouse inoculation to see if Toxoplasma parasites develop. Skin test antigen (toxoplasmin) (STA), and serological procedures such as the Complement Fixation Test (CF), Latex Flocculation Test (LF), Sabin and Feldman (SF), Indirect Haemagglutination Test (IHA), Indirect Immunofluorescence assay (IFI), and Enzyme-linked immunosorbet assay (ELISA) have been employed to detect specific antibodies in screening programs and also as adjuncts to the diagnosis of acute toxoplasmosis. More recently other methods have been developed such as Western-blot and detection of DNA with polymerase chain reaction (PCR) \[[@B1],[@B4]\].

Treatment for human toxoplasmosis is highly important for immunocompromised patients or acutely infected pregnant women. Various pharmacological agents are available such as pyrimethamine alone or combined with sulfadiazine. Atovaquone has been used as a second course of treatment for retinochoroiditis. Azithromycin is used as an alternative in the treatment of ocular and cerebral toxoplasmosis in AIDS patients, as well as, for active, non-vision-threatening toxoplasmic retinochoroiditis with satisfactory results \[[@B1],[@B13],[@B14]\].

The purpose of this systematic review and meta-analysis was to evaluate the seroprevalence of toxoplasmosis and its relationship with different risk factors. The understanding of these relationships can aid in the analysis of the epidemiological pattern of disease among different population groups and the epidemiologic shift of *T gondii* infection in Mexico.

Methods
=======

Ethical Aspects
---------------

This study was approved by the Ethical Committee of the Health Sciences Center of the University of Guadalajara \# C.I.100-2012.

Database search
---------------

Five databases were searched (Pub Med, Lilacs, Medline, Latindex and Google Scholar) from January to June of 2012. The following limits were applied: published January 1951 to 2012, the first case of human *T. gondii* infection was reported in an 11-month old girl from the Pediatric Hospital at Mexico City in 1950 \[[@B15]\], written in English or Spanish and undertaken in adults. The search terms were "infection with *Toxoplasma",* "toxoplasmosis", "epidemiology", "risk factors", "infection by *T. gondii*, Mexico" "anti-*Toxoplasma* antibodies" alone or combined.

Data collection
---------------

All retrieved studies were studied carefully by two investigators (GRML and BR). The extracted data included: year of publication, characteristics of the study population, location of the study, sample size, number of cases, diagnostic test and risk factors. Abstracts were included if considered acceptable, but were not included in the meta-analysis for risk factors. Reference lists of full-text publications and textbooks were also examined to identify studies not retrieved by the original search.

Data analysis
-------------

The crude prevalence data and the weighted prevalence were calculated for each study (Table [1](#T1){ref-type="table"}) \[[@B16]-[@B59]\]. Seven different types of diagnostic tests were identified during the literature search. Table [2](#T2){ref-type="table"} summarizes their main characteristics, sensitivity and specificity, and their timeline of employment in Mexico. Study groups were also stratified according to categories alone (Table [3](#T3){ref-type="table"}) or by combining the risk group and diagnostic test used in each study \[[@B60]-[@B66]\] (Table [4](#T4){ref-type="table"}).

###### 

Publications included for meta-analysis with diagnostic methods and population characteristics

  **Sequence**    **Year**       **First Author**           **State**        **Municipality**     **Test**   **Category**   **Number of cases**   **Positive cases**   **Prevalence (%)**   **Reference**
  -------------- ---------- --------------------------- ------------------ --------------------- ---------- -------------- --------------------- -------------------- -------------------- ---------------
  1                 1951              BiagiF.               Tamaulipas            Tampico           STA           GP                231                  108                   47            \[[@B16]\]
  2                 1952             Biagi F.                 México              Mexico            STA           IC                155                   58                  37.4           \[[@B49]\]
  3                 1952             Bustos C.               Veracruz             Orizaba           STA           GP                86                    31                   51            \[[@B17]\]
  4                 1953             Biagi F.                Campeche            Escarcega          STA           GP                132                   76                  56.8           \[[@B18]\]
  5                 1953             Varela G.           Estado de Mexico         Toluca            STA           GP                500                   81                   16            \[[@B19]\]
  6                                  Varela G.                Mexico              México            STA           CM                116                   19                   16            \[[@B19]\]
  7                                  Varela G.                Mexico              México            STA           CM                47                    7                   14.8           \[[@B19]\]
  8                                  Varela G.                Mexico              México            STA           CM                102                   13                  12.7           \[[@B19]\]
  9                                  Varela G.                                   Zoquiapan          STA           IC                107                   13                   14            \[[@B19]\]
  10                1954          Gutierrez E.B.              México              México            CFT           MI                58                    14                 24.14           \[[@B53]\]
  11                1955             Varela G.                Mexico              México             SF           GP                60                    16                  26.7           \[[@B20]\]
  12                                 Varela G.              Michoacan              N.E.              SF           GP                22                    6                   27.3           \[[@B20]\]
  13                                 Varela G.                Mexico              México             SF           GP                104                   39                  37.5           \[[@B20]\]
  14                                 Varela G.                Oaxaca              Oaxaca             SF           GP                276                   96                  34.8           \[[@B20]\]
  15                                 Varela G.              Tamaulipas             N.E.              SF           GP                230                   90                   39            \[[@B20]\]
  16                                 Varela G.               Yucatan               N.E.              SF           GP                17                    11                  64.7           \[[@B20]\]
  17                                 Varela G.           Distrito federal         Mexico             SF           MI                91                    54                   59            \[[@B20]\]
  18                                 Varela G.                Puebla               N.E.              SF           GP                44                    41                  93.2           \[[@B20]\]
  19                1957             Biagi F.                 México         Ixtapalapa, D.F.       STA           GP                272                   37                  13.6           \[[@B21]\]
  20                1961             Varela G.           Baja, California        Mexicali            SF           GP                73                    26                  35.9           \[[@B22]\]
  21                                 Varela G.              Chihuahua            Chihuahua           SF           GP                12                    3                    25            \[[@B22]\]
  22                                 Varela G.                México         Distrito Federal        SF           GP               2,463                 783                  31.8           \[[@B22]\]
  23                                 Varela G.               Hidalgo               Apan              SF           GP                409                  117                  28.6           \[[@B22]\]
  24                                 Varela G.           Estado de Mexico         Toluca             SF           GP                64                    15                  23.4           \[[@B22]\]
  25                                 Varela G.              Michoacan             Morelia            SF           GP                35                    11                 31.42           \[[@B22]\]
  26                                 Varela G.               Morelos              Various            SF           GP                208                   54                 25.96           \[[@B22]\]
  27                                 Varela G.               Nayarit               Tepic             SF           GP                112                   25                  22.3           \[[@B22]\]
  28                                 Varela G.                Oaxaca        Oaxaca and Tuxtepec      SF           GP                546                  107                 19.59           \[[@B22]\]
  29                                 Varela G.                Puebla              Puebla             SF           GP                170                   61                  35.9           \[[@B22]\]
  30                                 Varela G.              Queretaro             Various            SF           GP                90                    33                 36.66           \[[@B22]\]
  31                                 Varela G.               Sinaloa             Culiacan            SF           GP                311                  109                   35            \[[@B22]\]
  32                                 Varela G.               Sinaloa             Mazatlan            SF           GP                100                   16                   16            \[[@B22]\]
  33                                 Varela G.               Tabasco             Macuspana           SF           GP                108                   38                  35.2           \[[@B22]\]
  34                                 Varela G.              Tamaulipas        Ciudad Victoria        SF           GP                220                   39                  17.7           \[[@B22]\]
  35                                 Varela G.              Tamaulipas         Nuevo Laredo          SF           GP                100                   28                   28            \[[@B22]\]
  36                                 Varela G.               Tlaxcala            Tlaxcala            SF           GP                594                  144                  24.2           \[[@B22]\]
  37                                 Varela G.               Veracruz          Boca del Rio          SF           GP                93                    36                  38.7           \[[@B22]\]
  38                                 Varela G.               Veracruz            Soconusco           SF           GP                121                   39                  32.2           \[[@B22]\]
  39                                 Varela G.               Veracruz            Veracruz            SF           GP                125                   30                   24            \[[@B22]\]
  40                                 Varela G.               Yucatan              Merida             SF           GP                17                    11                  64.7           \[[@B22]\]
  41                1962            Carrillo C.               México              Mexico             SF           BD                232                   73                  31.4           \[[@B46]\]
  42                1965     Espinosa de los Reyes VM,        México              Mexico             SF           PW                329                  112                   34            \[[@B37]\]
  43                1966              Roch E.            Distrito Federal         México             SF           MW               2,320                 815                 35.13           \[[@B44]\]
  44                1966              Roch E.                 Mexico            All States           SF           GP              14,869                4,411                  30            \[[@B23]\]
  45                1972           Goldsmith RS.              Oaxaca         Puerto Escondido       IHA           GP                159                   2                   1.26           \[[@B24]\]
  46                1972           Goldsmith RS.              Oaxaca           Mixteca Alta         IHA           GP                114                   0                    0             \[[@B24]\]
  47                1972           Goldsmith RS.              Oaxaca              Ixtlan            IHA           GP                48                    2                   4.2            \[[@B24]\]
  48                1972           Goldsmith RS.              Oaxaca         Región del Valle       IHA           GP                150                   5                   3.3            \[[@B24]\]
  49                1972           Goldsmith RS.              Oaxaca            Tehuantepec         IHA           GP                137                   18                   13            \[[@B24]\]
  50                1974             Biagi F.                 Mexico              México             FL           WP                367                   73                  19.9           \[[@B35]\]
  51                1986         Fernandez Terrano           Tabasco        Region de los Rios     IFI-G          WP                125                   75                   60            \[[@B36]\]
  52                1989        Galvan-Ramirez ML.                                Jalisco          IFI-G          GP                807                   25                  3.1            \[[@B25]\]
  53                1989        Zavala-Velazquez J.          Yucatan              Merida           IFI-G          MW                100                   47                   47            \[[@B45]\]
  54                1991           Goldsmith RS.              Oaxaca         60 municipalities      IHA           GP               3,229                 124                  3.8            \[[@B26]\]
  55-86             1991       Velasco- Castrejon O.          Mexico            All states         IFI-G          GP              29,279                9,371                  32            \[[@B27]\]
  87                1995        Galvan-Ramirez ML.           Jalisco            Guadalajara       ELISA-G         PW                350                  122                  34.9           \[[@B39]\]
  88                             Galvan-Ramirez ML           Jalisco            Guadalajara       ELISA-G         MW                105                   48                  44.9           \[[@B39]\]
  89                             Galvan-Ramirez ML           Jalisco            Guadalajara       ELISA-G         PW                50                    13                 26.01           \[[@B39]\]
  90                1997         Galvan-Ramirez ML           Jalisco            Guadalajara       ELISA-G         IC                39                    27                  69.2           \[[@B50]\]
  91                             Galvan-Ramirez ML           Jalisco            Guadalajara       ELISA-G         IC                53                    19                  35.8           \[[@B50]\]
  92                1997              Tay J.              Distrito Fed.           México          ELISA-G         MI                328                  125                   38            \[[@B54]\]
  93                1998            Gongora R.               Yucatan              Mérida          ELISA-G         IC                95                    45                   47            \[[@B47]\]
  95                                Gongora R.               Yucatan              Mérida          ELISA-G         BD                100                   69                   69            \[[@B47]\]
  93                1999         Galvan-Ramirez ML           Jalisco            Guadalajara       ELISA-G        ORG                59                    38                   64             \[[@B7]\]
  96                2000          Kelso Santos E.           Nuevo Leon           Monterrey        ELISA-G         GP                400                   82                  20.5           \[[@B29]\]
  97                2003          Jaramillo P.J.         Estado de Mexico         Toluca          ELISA-G         PW                372                   47                 12.61           \[[@B40]\]
  98                2004         Galvan-Ramirez ML           Jalisco            Guadalajara       ELISA-G         PW                30                    14                   47            \[[@B38]\]
  99                             Galvan-Ramirez ML           Jalisco            Guadalajara       ELISA-G         PW                30                    13                   43            \[[@B38]\]
  100                            Galvan-Ramirez ML           Jalisco            Guadalajara       ELISA-G         PW                60                    17                  28.3           \[[@B38]\]
  101               2005         Galvan-Ramirez ML           Jalisco            Guadalajara       ELISA-G         BD                359                  104                   29             \[[@B5]\]
  102               2006       Alvarado-Esquivel C.           Durago            Guadalajara       ELISA-G         PW                343                   21                  6.1            \[[@B41]\]
  103               2007       Alvarado-Esquivel C.          Durango              Durango         ELISA-G         BD                432                   32                  7.4            \[[@B48]\]
  104               2008       Alvarado-Esquivel C.          Durango              Durango         ELISA-G        ORG                90                    19                  21.1           \[[@B58]\]
  105                          Alvarado-Esquivel C.          Durango              Durango         ELISA-G        ORG                83                    7                   8.4            \[[@B58]\]
  106               2008       Alvarado-Esquivel C.          Durango              Durango         ELISA-G         GP                187                   67                  35.8           \[[@B30]\]
  107               2008       Alvarado-Esquivel C.          Durango              Durango         ELISA-G         GP                121                   20                  16.5           \[[@B30]\]
  108               2008       Alvarado-Esquivel C.          Durango              Durango         ELISA-G         GP                155                   23                  14.8           \[[@B30]\]
  109               2008        Galvan-Ramirez ML.           Jalisco            Guadalajara       ELISA-G        ORG                145                  104                   72             \[[@B6]\]
  110               2009       Alvarado-Esquivel C.          Durango            Guadalajara       ELISA-G         PG                439                   36                  8.2            \[[@B42]\]
  111               2009         Cañedo-Solares I.       Distrito Federal         Mexico          ELISA-G         PG                100                   30                   30            \[[@B43]\]
  112               2010       Alvarado-Esquivel C.          Durango              Durango         ELISA-G         GP                248                   22                   8             \[[@B31]\]
  113               2010       Alvarado-Esquivel C.          Durango              Durango         ELISA-G         GP                61                    4                   6.6            \[[@B56]\]
  114                          Alvarado-Esquivel C.          Durango              Durango         ELISA-G         GP                203                   17                  8.4            \[[@B56]\]
  115                          Alvarado-Esquivel C.          Durango              Durango         ELISA-G         GP                168                   10                  6.6            \[[@B56]\]
  116               2010       Alvarado-Esquivel C.           Durago              Durango         ELISA-G         GP                152                   46                   30            \[[@B31]\]
  117               2010         Galvan-Ramirez ML           Jalisco            Guadalajara       ELISA-G         GP                174                   30                  17.8           \[[@B28]\]
  118               2010       Alvarado-Esquivel C.          Durango              Durango         ELISA-G         CM                85                    7                   8.2            \[[@B51]\]
  119                          Alvarado-Esquivel C.          Durango              Durango         ELISA-G         CM                50                    5                    10            \[[@B51]\]
  120                          Alvarado-Esquivel C.          Durango              Durango         ELISA-G         CM                234                   28                   12            \[[@B51]\]
  121                          Alvarado-Esquivel C.          Durango              Durango         ELISA-G         IC                103                   7                   6.8            \[[@B51]\]
  122               2011       Alvarado-Esquivel C.          Durango              Durango         ELISA-G        ORG                124                   8                    7             \[[@B57]\]
  123               2011       Alvarado-Esquivel C.          Durango              Durango         ELISA-G         MI                50                    10                   20            \[[@B55]\]
  124               2011       Alvarado-Esquivel C.          Durango              Durango         ELISA-G         GP                150                   8                   5.3            \[[@B32]\]
  125               2011       Alvarado-Esquivel C.          Durango              Durango         ELISA-G         IC                75                    10                  13.3           \[[@B52]\]
  126                          Alvarado-Esquivel C.          Durango              Durango         ELISA-G         GP                150                   16                  10.7           \[[@B52]\]
  127               2011       Alvarado-Esquivel C.          Durango              Durango         ELISA-G         GP               1,101                  76                  6.9            \[[@B59]\]
  128                          Alvarado-Esquivel C.          Durango              Durango         ELISA-G         CM                55                    9                   16.4           \[[@B59]\]
  129               2011       Alvarado-Esquivel C.          Durango              Durango         ELISA-G         GP                974                   59                  6.1            \[[@B32]\]
  130               2012       Alvarado-Esquivel C.          Durango              Durango         ELISA-G         GP                133                   11                  8.3            \[[@B33]\]
  131                          Alvarado-Esquivel C.          Durango              Durango         ELISA-G         GP                266                   14                  5.3            \[[@B33]\]
  132               2012       Alvarado-Esquivel C.          Durango              Durango         ELISA-G         GP                156                   35                  22.4           \[[@B34]\]
  **Total**                                                                                                                     **70,123**            **19,262**                                   

Skin test antigen (toxoplasmin) (STA); Complement Fixation Test (CF); Latex Flocculation Test (LF); Sabin & Feldman (SF); Indirect Haemagglutination Test (IHA); Enzyme-linked immunosorbet assay and type of antibody detected (ELISA-G), Indirect Immunofluorescence assay and type of antibody detected (IFI-G); General Population (GP); Pregnant Women (PW); Blood Donors (BD); Patients with Comorbidity (CM); Immunocompromised patients (IC); Women with Miscarriages (MW); Mentally-ill patients (MI); Other risk groups (ORG).

###### 

Diagnostic methods

  **Diagnostic test**                                                                                               **Fundament**                                                                     **Sensitivity**   **Specificity**   **Timeline**                                      **References**
  ---------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------- ----------------- ----------------- -------------- ---------------------------------------------------------------------------------------
  Skin test antigen (STA                                                           Type IV cell-mediated hypersensitivity reaction against the *T.gondii* antigen.                                          80%               70%          1950-1951                                \[[@B16]-[@B19],[@B21],[@B49]\]
  Sabin and Feldman Dye Test (SF).                             The gold standard. A dye test in which the serum antibodies alter the staining pattern of the *T. gondii* tachyzoites.                       96%               98%          1955-2005                         \[[@B20],[@B22],[@B23],[@B37],[@B44],[@B46]\]
  Complement Fixation Test (CF).                                     Antigen-antibody complexes are formed and detected by using a standard system with hemolisin and complement                           97.1%             64.5%         1954-1982                                          \[[@B53]\]
  Látex Flocculation Test (LF).                                                           This test uses latex particles for antigen-antibody flocculation.                                            No reported.          1974          \[[@B35]\]   
  Indirect Fluorescent Antibody Test (IFI).           Tachyzoites are fixed on a slide and exposed to test serum, then washed and exposed to a standard antibody labeled with fluorescent dye.              95%               96%         1986 to date                    \[[@B5],[@B25],[@B27],[@B28],[@B36],[@B38],[@B54]\]
  Indirect Haemagglutination Test (IHA).                                This test uses sheep red cells exposed to tannic acid and then to the soluble antigen fixed at 37 °C.                               95%               96%         1972 to 1989                                     \[[@B24],[@B26]\]
  Enzyme-linked immunoabsorbent assay (ELISA).    The ELISA detects *T. gondii*immunoglobulin IgG e IgM in serum and other body fluids with antibodies marked with peroxidase and fosfatase enzymes        100%              98.4%        1995 to date   \[[@B6],[@B7],[@B29]-[@B34],[@B39]-[@B43],[@B47],[@B48],[@B50]-[@B52],[@B55],[@B56]\]

###### 

**Crude and weighted*Toxoplasma*infection prevalence in low and high risk groups of Mexican population**

  **Population studied**        **Number of studies**   **Number of cases**   **Positive cases**   **A/Nx100 Crude prevalence (%)**   **Weighed prevalence (%)**   **CI 95% Lower-upper limit (%)**                             **References**
  ---------------------------- ----------------------- --------------------- -------------------- ---------------------------------- ---------------------------- ---------------------------------- --------------------------------------------------------------------
  **Low Risk Groups**                                                                                                                                                                                
  General population                     90                    61536                16855                       27.39                           20.26                        18.78-19.36              \[[@B16]-[@B24],[@B34],[@B51],[@B52],[@B55],[@B56],[@B58],[@B59]\]
  Pregnant Women                         12                    2595                  573                        22.08                           15.62                        14.30-16.93                                      \[[@B35]-[@B43]\]
  Blood Donors                            4                    1123                  278                        24.76                           17.035                       15.03-19.03                                   \[[@B5],[@B46]-[@B48]\]
  Patients with comorbidity               7                     689                   88                        12.77                           12.27                         9.83-14.72                                   \[[@B19],[@B51],[@B59]\]
  **High Risk Groups**                                                                                                                                                                               
  Women with miscarriages                 3                    2525                  910                        36.03                           35.96                         34.1-37.83                                   \[[@B39],[@B44],[@B45]\]
  Immunocompromised patients              7                     627                  179                        28.54                            20.2                        17.35-23.05                               \[[@B19],[@B47],[@B49]-[@B52]\]
  Mentally-ill patients                   4                     527                  203                        38.52                           37.24                        33.24-41.26                                   \[[@B20],[@B53]-[@B55]\]
  Other risk groups                       5                     501                  176                        35.13                           21.88                         19.0-24.76                                \[[@B6],[@B7],[@B57],[@B58]\]
  **Total**                            **132**              **70,123**            **19,262**                                                                                                         

###### 

**Weighted prevalence of*T. gondii*infection adjusted by risk factor (with or without) and diagnostic method**

  **Population studied-diagnostic method**    **Number of groups**   **Number of cases**   **Positive cases**   **A/Nx100 prevalence (%)**   **Meta-analysis prevalence (%)**   **Lower limit (%)**   **Upper limit (%)**
  ------------------------------------------ ---------------------- --------------------- -------------------- ---------------------------- ---------------------------------- --------------------- ---------------------
  with Risk - STA                                      4                     480                  103                     21.45                           13.39                        10.35                 16.44
  without Risk -STA                                    6                    1268                  340                     22.81                           22.48                        20.32                 24.65
  without Risk-LF                                      1                     367                   73                     19.89                           19.89                        15.8                  23.97
  without-risk CF                                      1                     58                    14                     24.14                           22.16                        13.64                 35.15
  without Risk-SF                                      32                   22245                 6674                      30                              30                         29.4                  30.59
  with Risk-SF                                         1                    2320                  815                     35.13                           35.12                        33.18                 37.18
  without Risk-IFI-G                                   36                   29997                 9597                    31.99                            29.3                        28.81                 29.79
  with Risk-IFI-G                                      5                    1295                  224                     16.77                            5.58                        4.44                  6.77
  without Risk-IHA                                     6                    3837                  151                      3.94                            2.63                        1.24                  4.02
  with Risk-ELISA-G                                    18                   1963                  523                     26.64                           17.66                        16.17                 19.15
  without Risk-ELISA-G                                 22                   6293                  748                     11.89                            8.92                        8.24                   9.6
  **Total**                                         **132**              **70,123**            **19,262**                                                                                            

Complement Fixation (CF), Skin test antigen toxoplasmin (STA), Latex Floculation (LF), Sabin and Feldman (SF), Indirect Hemaglutination (IHA), Indirect Fluorescence (IFI), Enzyme-linked immunosorbet assay (ELISA). All prevalences calculated by meta-analysis were statistically significant (p \< 0.001).

The study groups were divided into: 1) Individuals with risk factors were designated as high risk groups that included: women who had had abortions, immunocompromised patients with AIDS or HIV, leprous people, patients with neurological disorders, pet-cat, owners and slaughterhouse workers; 2) Individuals without risks factors were designated in low risk groups: blood donors, general population and normal pregnant women.

Statistical methods
-------------------

### ***Crude prevalence***

The crude prevalence of each study group was estimated to assess the amount of affection by the disease expressed in percentage of positives cases in relation to all cases analyzed. It was calculated as the number of positive cases divided by the sample size of the cohort in each study group.

### ***Weighted population prevalence (WP)***

The assessment of the prevalence of *T. gondii* of the different study groups was estimated by using the weighed population prevalence, given that not all the studies included the same number of individuals. This strategy restricts the bias that may impose the heterogeneous nature of the reports, and has proven to be valid when combining a number of studies with inherent heterogeneity in sample size and effects \[[@B67]\].

Each crude prevalence was multiplied by a "weight", which was proportional to the number of subjects included in the sample, i.e., in large samples, the prevalence found outweighs that of small samples. This prevalence is obtained by summing the product of the prevalence for its "weight" of the sum of the "weights". This estimate is more accurate than the overall crude prevalence to estimate the true prevalence of a cumulative set of groups. The formula to calculate the population prevalence (weighed prevalence, WP) of *T. gondii* in all groups or subgroups, included in this meta-analysis was P = ∑ (pi)(1/vi)/∑ 1/vi as explained by Borenstein et al. \[[@B68]\].

Definitions
-----------

i = Number of studies in each group. Ni = Total number of cases in each study, Ai = Number of positive cases from each study, (Ni-Ai) is the number of negative cases in each study. The risk of infection as a proportion in each study (pi) was calculated as Ai/Ni. The variance of each study (vi) was calculated as Ai (Ni-Ai)/Ni^3^. The standard error (SEi) of each study was estimated as √ vi.

The total population variance (V) was estimated as 1/ ∑ 1/vi. The standard error of the population was calculated as SE = √V. The confidence interval (C.I.95%) for the population prevalence was obtained by P + 1.96 SE (upper limit) and P-1.96 EE lower limit. The probability that the prevalence could be different from zero was calculated with a Z test, Z = P/SE.

### ***Forest plot***

A Forest Plot chart was built in order to provide a comprehensive analysis of the studies included in the meta-analysis according to its odd ratio and confidence interval (CI) \[[@B68]\].

### ***Linear regression analysis***

A bivariate linear regression analysis was conducted to determine the relationship between the seroprevalence of *Toxoplasma* infection over time. The regression coefficient was calculated by the equation (y = a + b x), a = ordinate of origin, b = slope and the R^2^ and p were obtained with the SPSS program (Version 18). The epidemiological behaviour of the prevalence of *Toxoplasma* infection was estimated by plotting the year of each publication date (independent variable) starting at year 1951 until 2012 versus the relative prevalence (dependent variable) reported in each study \[[@B68]\].

Results
=======

From the five databases, a total of 45 publications were eligible that included 132 studies and 70,123 individuals, and 19,262 positive cases as shown in Table [1](#T1){ref-type="table"}. As shown in Table [3](#T3){ref-type="table"}, most of the studies were carried out in low risk groups, such as, the general population (n = 90 studies) followed by pregnant women (n = 12), with the least number of studies in blood donors (n = 4). In the high-risk groups, relatively fewer studies have been carried out; women with miscarriage (n = 3), immuno-compromised patients (n = 7), mentally-ill patients (n = 4), other risk groups (n = 5) and patients with nonrelated comorbidity (n = 7). To the best of our knowledge, all the studies included in this meta-analysis had a cross-sectional design and were aimed to identify the prevalence of *T. gondii* antibodies in a cohort. No prospective or follow-up studies aimed to seek seroconversion or self-reported results were detected.

Meta-analysis in low risk groups
--------------------------------

### ***General population***

Most of the studies were carried out in low risk groups such as the general population (90 studies) that gave a total of 61,536 people tested for *T. gondii infection*. The WP was 20.26% (CI~95%~18.78% -- 19.36%) with a variance of 0.0002% and a standard error of 0.1463%, Z = 130.391 and p \<0.001 (Table [3](#T3){ref-type="table"}).

### ***Pregnant women***

In this study group, 12 publications included 2,595 pregnant women. The WP was 15.62% (CI~95%~14.30%-16.93%), with a variance of 0.0045% and standard error of 0.67%, Z = 23.313 and p \<0.001 (Table [3](#T3){ref-type="table"}).

### ***Blood donors***

In 4 studies, a total of 1123 blood donors were tested. The WP was 17.03% (CI~95%~ 15.03% -- 19.03%) with a variance of 0.00104% and standard error of 1.0213%, Z = 16.679 and p \<0.001 (Table [3](#T3){ref-type="table"}).

### ***Patients with comorbidity***

In 689 cases from seven studies, a WP of 12.27% (CI~95%~ 9.83 -- 14.72) was found with a variance of 0.0155%, standard error of 1.2463%, Z = 9.85 and p \<0.001 (Table [3](#T3){ref-type="table"}).

Meta-analysis in high-risk groups
---------------------------------

### ***Women with miscarriages***

In 3 studies, 2595 women were tested. The WP was 35.96% (CI~95%~ 34.10% - 37.83%) with a variance of 0.0091% and standard error of 0.9532%, Z = 37.73 and p \<0.001 (Table [3](#T3){ref-type="table"}).

### ***Immunocompromised patients***

In this study group, 627 patients from seven studies were included. The WP was 20.20% (CI~95%~ 17.35%- 23.05%) with a variance of 0.0211% and standard error of 1.45%, Z = 13.90 and p \<0.0001 (Table [3](#T3){ref-type="table"}).

### ***Mentally-ill patients***

A total of 527 mentally-ill patients were included from four studies. The WP was 37.24% (CI~95%~ 33.24% - 41.26%) with a variance of 0.0994% and standard error of 3.15%, Z = 11.43 and p \<0.001 (Table [3](#T3){ref-type="table"}).

### ***Other risk groups***

In 501 cases from five studies, a WP of 21.88% (CI~95%~ 19.00% - 24.76%) was found with a variance of 0.0215%, standard error of 1.46%, Z = 14.91 and p \<0.001 (Table [3](#T3){ref-type="table"}).

### ***Weighted prevalence by diagnostic test and risk factors***

In order to determine, if the prevalence of *T. gondii* was based on the diagnostic test, the study groups were adjusted by diagnostic test and risk factors reported. Only the studies that used the SF assay and ELlSA showed a correlation between the low and high risk. Interestingly, the rest of the diagnostic tests showed a lower prevalence, although it is noteworthy to mention that the difference may be due to the number of cases in the risk group categories (Table [4](#T4){ref-type="table"}).

### ***Epidemiological transition of Toxoplasma infection in Mexico***

Figure [1](#F1){ref-type="fig"} illustrates the Forest Plot analysis of the WP (CI~95%~) of each study included in this meta-analysis. The linear regression analysis of *Toxoplasma* infection in the Mexican population over a time span of 60 years showed a downward trend of 0.1%/year that represents an overall 5.8% reduction of infection (R^2^ = 0.0354 and F (1) =4.802, p \> 0.05) that was not statistically significant (Figure [2](#F2){ref-type="fig"}).

![**Epidemiological transition of the*T. gondii*infection from 1954 to 2012, (―) Linear regression and triangle (♦) is the individual prevalence of*Toxoplasma gondii*infection reported in each study group.**The decrement in the prevalence rate was 0.1%/year. The R^2^value was not statistically significant (NS).](1756-3305-5-271-1){#F1}

![**Weighted prevalence of*Toxoplasma gondii*infection from 132 studies.**Forest plot shows event numbers, total numbers and confidence intervals for all study groups included in the meta-analysis. The triangle (♦) represents the prevalence of each study and (┬ ┴) are intervals of confidence.](1756-3305-5-271-2){#F2}

Discussion
==========

The questions that led us to achieve this study were if Mexico had a significant prevalence of toxoplasmosis, and if there have been changes in the epidemiology of this disease from 1951 to date. Five databases were searched, and 132 studies were selected involving 70,123 individuals and 19,262 positive cases.

This study showed that the WP of toxoplasmosis in Mexico was 20.26%, which is relatively low compared to the mean prevalence of 32% reported in 1991 \[[@B27]\]. This can be explained if we note that variations between methodologies can result in heterogeneity of the estimations. However, despite this situation, at least 20.26% of Mexicans may have been exposed to toxoplasmosis.

Between 1951 and 1958, the STA was an appropriate test since, at that time, it was a rapid and sensitive assay for epidemiological studies. It did not give cross-reactions with other parasites, but it did make a fair amount of false-negatives in mild infections. This was one of its disadvantages when used for a survey in the general population in Tamaulipas, Campeche and Mexico City (1953). The WP was 21.31% in 11 study groups with 1846 cases \[[@B16]-[@B20]\]. Since only one study was performed by the FL test with 367 individuals, and another study included 58 cases tested by fixation complement, we were not able to compare these results against the SF or IFI assays.

The SF test was used in epidemiological studies carried out between 1961 and 1966. The CP and WP was 30% and 35.12%, respectively \[[@B23]\]. The advantage of this test is that it is a gold standard, and it is highly sensitive, although the disadvantage is that it requires live parasites. The global prevalence during that time was 14.92%, which is closer, to the prevalence of 8.26% aforementioned. In the same period, the IFI test was introduced and was then used in the largest survey carried out in Mexico (1992) with 29, 279 people with a mean prevalence of 32.0% \[[@B27]\]. The meta-analysis of all tests performed with IFI was 29.32%, because the majority of studies have used this method (31,412 cases).

In the 80s, the ELISA methods were introduced with higher sensitivity and specificity that reduced the number of cross-reactions. Interestingly, the WP was lower, ranging from 8.92% to 17.66%, which may have been caused by the lower number of cases, (8256 cases), less than one-third of the studies, when compared to the 26,751 cases tested with SF and the 30,485 cases with IFI.

The general population involved 61,536 cases with a WP of 20.26%, while the mean prevalence was reported as 32% in 1991 \[[@B27]\]. This discrepancy may be caused by the differences in the diagnostic methods that are then adjusted when the weighted prevalence was estimated \[[@B27]\].

Pregnant women presented a WP of 15.62% with an upper limit of 16.93% that is closer to the general population prevalence (20.26%), which is reasonable since these women did not have obstetric complications. These values were lower compared to 45.8% and 30.5%, respectively for specific IgG antibodies detected by the Sabin-Feldman dye test in two separate studies among pregnant women \[[@B69]\], however, our results were higher than 0.6% among pregnant women in Norway \[[@B70]\].

In the four studies performed in blood donors, the WP was 17.03% among 1123 cases. This prevalence is also closer to the general population prevalence, despite that each one of them was carried out with different diagnostic tests (one with SF \[[@B46]\], one not reported \[[@B47]\], one with IFAT \[[@B5]\] and one with ELISA, respectively \[[@B48]\]).

Regarding the blood donors group, this group has a lower WP when compared to the general population. Transfusion Medicine guidelines have pronounced that donated blood should be screened for toxoplasmosis, because of the potential risk for blood receptors receiving transfusions from subjects in the acute phase of infection. Therefore, testing of toxoplasmosis in blood donations should be mandatory in the country \[[@B5],[@B46]-[@B48]\].

Three studies performed in Mexico were in women with miscarriages having primary infection during pregnancy. There were clear differences between the WP of pregnant women 15.62% whereas those with miscarriages had 35.96% (p \<0.05). These results are concordant with other studies that have shown an association between high prevalence of miscarriages and *Toxoplasma* infection \[[@B39],[@B44],[@B45]\].

Another risk group was the immunocompromised patients. Among 627 cases, the WP of 20.2% was the same as in the general population. One explanation is that the patients were diagnosed by different methods, and two studies performed in Durango had the lowest prevalence \[[@B47],[@B49]-[@B52]\].

The highest WP was 37.24% in the mentally-ill patients, at least 18.27% higher than the general population \[[@B55]\]. Several authors have reported a high prevalence of *Toxoplasma* antibodies in patients with schizophrenia, although other factors such as genetic may be present in the schizophrenia, different reports have shown that Toxoplasma is somehow associated with cases of schizophrenia. This finding justifies the need to examine the relationship between toxoplasmosis and schizophrenia with pre-clinical and clinical trials aimed to improve prevention and treatment programs in patients with psychiatric illness \[[@B71],[@B72]\]. On the other hand, a meta-analysis of latent *Toxoplasma gondii* infection in immunocompetent hosts and cryptogenic epilepsy showed a strong association between seroprevalence rates for toxoplasmosis and prevalence rates of epilepsy. If an etiological connection can be proven, it would have implications for the implementation of prevention and treatment strategies for Toxoplasma disease \[[@B73]\].

Cat owners and slaughterhouse workers presented both a CP and WP of 21.88% each. This may be because only five studies with 501 individuals with this attribute were analyzed. Regarding patients with nonrelated comorbidity, WP was 12.28%, lower than in the general population. Three groups were studied with STA and four more from Durango had the lowest prevalence in the country, which may show that their comorbidity was not related to the risk of infection.

Another important factor is the difference in the prevalence of *T. gondii* infections due to the sensitivity and specificity of diagnostic tests, since there are several methods to identify and evaluate antibodies in individuals who were infected by the parasite. Over time, at least four different diagnostic assays have been used worldwide that range from the lowest specificity and sensitivity like the STA progressing on to the SF Dye Test and other similar tests up to the improved ELISA (Table [2](#T2){ref-type="table"}) \[[@B7],[@B74]\].

In regards to the analysis of the study groups adjusted by risk factors (with or without) and diagnostic test, we found that only those tested by ELISA showed a WP of 17.66% in the risk factor groups against a WP of 8.92% in the groups without risk factors. However, with the other methods, both crude and weighted prevalence were reduced; however, the number of studied individuals was higher. This analysis demonstrates that the prevalence varies according to the diagnostic method and by the number of individuals tested in each study group (Figure [2](#F2){ref-type="fig"}).

The epidemiological behavior of *Toxoplasma* infection showed a negative slope of -0.1%/year, which represented an accumulated decrement of nearly 6% in the prevalence of infection in Mexico after 60 years. This may suggest that we have not paid enough attention to *T. gondii* infection as a public health problem though it tends to decrease. However, another key issue is that if the studies carried out in the first 10 years had been tested with ELISA then the decrement would have been even lower (Figure [2](#F2){ref-type="fig"}).

In this study, stratification of studies based on molecular assays was not feasible because none was reported. However, genotyping has been reported in other Latin American populations, such as Colombia where a virulent strain (LD~100~ of 10 tachyzoites) was identified as clonal type 1 (CIBMUQ/HDC) \[[@B75]\]. Additionally, in another study, the GRA6 type I/III profile was the most frequent among asymptomatic cases (68/148, 45.9%) and in severe multi visceral cases (2/4, 50%). Furthermore, GRA6 type II, was found in one case of congenital toxoplasmosis, one case of severe multi visceral infection, one case of ocular infection, and in five cases (5/148,3.4%) of asymptomatic patients \[[@B76]\]. Further studies based on genetic-based diagnostic assays will be relevant in the future, since *Toxoplasma gondii* isolates from Latin America have mixed/ recombinant genetic structure.

A 6% decrement in the prevalence of *Toxoplasma* infection after 60 years of studies was detected. This decrement is quite low after a relatively long period, contrary to what has been reported in the United States, with a 14% decrement in only one decade \[[@B77]\]. Therefore, our data warrants that researchers must pay more attention to this disease and to communicate to the medical community the need of improvement of the prevention strategies, together with effective diagnostic testing and management of patients in high risk of infection such as immunocompromised patients and pregnant women.

Further research is still required to understand and clarify the role of *T*. *gondii* in its diverse routes of transmission, as well as to design better control measures that focus on minimizing the risk of infection. The purpose of such studies should be to aid in the monitoring of changes in the epidemiology of *T. gondii* infection, and to strengthen educational efforts in order to avoid the transmission of infection in populations that cannot be controlled by drugs alone.

Implications for research
-------------------------

A crucial factor is the difference in the prevalence of *T. gondii* infections due to the sensitivity and specificity of the diagnostic tests, since there are several methods to identify and evaluate antibodies in individuals who were infected by the parasite. At least four different diagnostic assays have been used in this study, that range from the lowest specificity and sensitivity like the CF, progressing on to the SF dye test and other similar tests up to the improved ELISA.

Conclusion
==========

In conclusion, to the best of our knowledge, this is the first study that provides a comprehensive view of the epidemiological situation on the prevalence of *T. gondii* infection among the adult Mexican population. It provides not only epidemiologic evidence relevant to Mexico, but to other countries in the Americas and worldwide as well, where it has been documented that *T. gondii* prevalence is shifting, related to regional climate changes among other factors. In this study, the major risk groups with Toxoplasma infection were women with miscarriages, immunocompromised patients, mentally-ill patients and other risk groups. Noteworthy was the psychiatric patients group, since *T.gondii* can cause serious damage to the central nervous system.
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